Smith & Nephew SNATS, Inc. (NYSE:SNN) Receives $35.75 Consensus Price Target from Brokerages

Shares of Smith & Nephew SNATS, Inc. (NYSE:SNN) have been assigned a consensus recommendation of “Hold” from the six ratings firms that are covering the firm, MarketBeat Ratings reports. Five equities research analysts have rated the stock with a hold recommendation and one has given a strong buy recommendation to the company. The average 1 year target price among brokers that have covered the stock in the last year is $35.75.

Several equities research analysts have issued reports on SNN shares. Weiss Ratings reiterated a “hold (c+)” rating on shares of Smith & Nephew SNATS in a research report on Wednesday, January 21st. Wall Street Zen raised shares of Smith & Nephew SNATS from a “buy” rating to a “strong-buy” rating in a report on Saturday, January 10th. Canaccord Genuity Group reduced their target price on Smith & Nephew SNATS from $36.00 to $34.00 and set a “hold” rating on the stock in a research note on Tuesday, November 11th. Royal Bank Of Canada downgraded Smith & Nephew SNATS from an “outperform” rating to a “sector perform” rating in a research report on Monday, December 15th. Finally, Kepler Capital Markets upgraded Smith & Nephew SNATS to a “strong-buy” rating in a report on Monday, November 17th.

Institutional Inflows and Outflows

Several large investors have recently made changes to their positions in SNN. Bank of Montreal Can boosted its stake in shares of Smith & Nephew SNATS by 321.6% in the 2nd quarter. Bank of Montreal Can now owns 3,429,829 shares of the medical equipment provider’s stock valued at $105,056,000 after purchasing an additional 2,616,301 shares in the last quarter. River Road Asset Management LLC lifted its stake in Smith & Nephew SNATS by 9.3% in the second quarter. River Road Asset Management LLC now owns 3,179,814 shares of the medical equipment provider’s stock worth $97,175,000 after purchasing an additional 270,480 shares during the last quarter. Goldman Sachs Group Inc. boosted its position in Smith & Nephew SNATS by 5.2% during the fourth quarter. Goldman Sachs Group Inc. now owns 2,053,726 shares of the medical equipment provider’s stock valued at $67,383,000 after buying an additional 100,697 shares during the period. Brandes Investment Partners LP grew its stake in shares of Smith & Nephew SNATS by 4.1% during the second quarter. Brandes Investment Partners LP now owns 1,604,400 shares of the medical equipment provider’s stock valued at $49,143,000 after buying an additional 63,778 shares during the last quarter. Finally, JPMorgan Chase & Co. increased its holdings in shares of Smith & Nephew SNATS by 6,663.4% in the second quarter. JPMorgan Chase & Co. now owns 1,210,655 shares of the medical equipment provider’s stock worth $37,082,000 after buying an additional 1,192,755 shares during the period. 25.64% of the stock is owned by hedge funds and other institutional investors.

Smith & Nephew SNATS Stock Performance

NYSE:SNN opened at $36.16 on Monday. The company has a quick ratio of 1.40, a current ratio of 3.00 and a debt-to-equity ratio of 0.60. The business’s 50-day moving average price is $33.48 and its two-hundred day moving average price is $34.77. Smith & Nephew SNATS has a twelve month low of $23.91 and a twelve month high of $38.79.

About Smith & Nephew SNATS

Smith & Nephew plc is a global medical technology company specializing in the design, development and manufacture of advanced surgical devices, orthopaedic reconstruction implants, trauma and extremities products, sports medicine solutions and wound care therapies. Founded in 1856 in Hull, United Kingdom, the company has grown through both organic innovation and strategic acquisitions to offer a broad portfolio that addresses patient needs across joint replacement, minimally invasive surgery and wound healing.

In its orthopaedics business, Smith & Nephew provides hip and knee replacement systems, modular joint revision implants and biologic solutions for bone repair.